These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

860 related items for PubMed ID: 3103805

  • 1. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F.
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [Abstract] [Full Text] [Related]

  • 2. Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).
    Murphy DL, Karoum F, Pickar D, Cohen RM, Lipper S, Mellow AM, Tariot PN, Sunderland T.
    J Neural Transm Suppl; 1998 Feb; 52():39-48. PubMed ID: 9564606
    [Abstract] [Full Text] [Related]

  • 3. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
    Fuller RW, Hemrick-Luecke SK, Kindt MV, Heikkila RE.
    Life Sci; 1988 Feb; 42(3):263-71. PubMed ID: 3121972
    [Abstract] [Full Text] [Related]

  • 4. Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine-like monoamine oxidase B inhibitors.
    Yu PH, Davis BA, Durden DA, Barber A, Terleckyj I, Nicklas WG, Boulton AA.
    J Neurochem; 1994 Feb; 62(2):697-704. PubMed ID: 8294932
    [Abstract] [Full Text] [Related]

  • 5. Reciprocal changes in striatal dopamine and beta-phenylethylamine induced by reserpine in the presence of monoamine oxidase inhibitors.
    Juorio AV, Greenshaw AJ, Wishart TB.
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Dec; 338(6):644-8. PubMed ID: 3149722
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Epinephrine accumulation in rat brain after chronic administration of pargyline and LY 51641--comparison with other brain amines.
    Mefford IN, Roth KA, Jurik SM, Collman V, McIntire S, Tolbert L, Barchas JD.
    Brain Res; 1985 Jul 29; 339(2):342-5. PubMed ID: 2411347
    [Abstract] [Full Text] [Related]

  • 8. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
    Bondiolotti GP, Galva MD, Villa F, Sciaba L, Picotti GB.
    Biochem Pharmacol; 1995 Jun 29; 50(1):97-102. PubMed ID: 7605351
    [Abstract] [Full Text] [Related]

  • 9. Lesion-induced reductions in trace amine accumulation: dependence on MAO inhibitor pretreatment.
    Nguyen TV, Juorio AV, Greenshaw AJ.
    Brain Res Bull; 1989 Feb 29; 22(2):197-200. PubMed ID: 2495844
    [Abstract] [Full Text] [Related]

  • 10. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
    Severina IS.
    Biokhimiia; 1979 Feb 29; 44(2):195-207. PubMed ID: 435561
    [Abstract] [Full Text] [Related]

  • 11. Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium.
    Lenzen S, Nahrstedt H, Panten U.
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Nov 29; 324(3):190-5. PubMed ID: 6419132
    [Abstract] [Full Text] [Related]

  • 12. Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus.
    Yu PH, Davis BA, Fang J, Boulton AA.
    J Neurochem; 1994 Nov 29; 63(5):1820-8. PubMed ID: 7931338
    [Abstract] [Full Text] [Related]

  • 13. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
    Youdim MB, Tipton KF.
    Parkinsonism Relat Disord; 2002 Mar 29; 8(4):247-53. PubMed ID: 12039419
    [Abstract] [Full Text] [Related]

  • 14. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
    Tadano T, Satoh S, Satoh N, Kisara K, Arai Y, Kim SK, Kinemuchi H.
    J Pharmacol Exp Ther; 1989 Jul 29; 250(1):254-60. PubMed ID: 2501477
    [Abstract] [Full Text] [Related]

  • 15. Monoamine oxidase in bovine thyroid tissue.
    Masini-Repiso AM, Cabanillas AM, Andrada MC, Coleoni AH.
    Horm Metab Res; 1986 Nov 29; 18(11):750-3. PubMed ID: 3098663
    [Abstract] [Full Text] [Related]

  • 16. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P, Youdim MB.
    J Neurochem; 1986 May 29; 46(5):1359-65. PubMed ID: 2420928
    [Abstract] [Full Text] [Related]

  • 17. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats.
    Kato T, Dong B, Ishii K, Kinemuchi H.
    J Neurochem; 1986 Apr 29; 46(4):1277-82. PubMed ID: 2419508
    [Abstract] [Full Text] [Related]

  • 18. Monoamine receptor sensitivity changes following chronic administration of MDL 72394, a site-directed inhibitor of monoamine oxidase.
    Palfreyman MG, Mir AK, Kubina M, Middlemiss DN, Richards M, Tricklebank MD, Fozard JR.
    Eur J Pharmacol; 1986 Oct 14; 130(1-2):73-89. PubMed ID: 3780861
    [Abstract] [Full Text] [Related]

  • 19. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A, Brewer F, Johnson ES, Mallard N, Hartig F, Taylor S, Corn TH.
    J Neural Transm (Vienna); 2003 Nov 14; 110(11):1241-55. PubMed ID: 14628189
    [Abstract] [Full Text] [Related]

  • 20. Absence of 2-phenylethylamine binding after monoamine oxidase inhibition in rat brain.
    Li XM, Juorio AV, Paterson IA, Boulton AA.
    Eur J Pharmacol; 1992 Jan 14; 210(2):189-93. PubMed ID: 1601056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.